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Clinical application of
autologous technetium-
99m-labelled eosinophils to
detect focal eosinophilic
inﬂammation in the lung
Abstract
The detection of focal eosinophilic
inﬂammation by non-invasive means may aid
the diagnosis and follow-up of a variety of
pulmonary pathologies. All current methods of
detection involve invasive sampling, which
may be contraindicated or too high-risk to be
performed safely. The use of injected
autologous technetium-99m (Tc-99m)-labelled
eosinophils coupled to single-photon emission
computed tomography (SPECT) has been
demonstrated to localise eosinophilic
inﬂammation in the lungs of a patient with
antineutrophil cytoplasmic antibody-positive
vasculitis. Here, we report on the utility of this
technique to detect active eosinophilic
inﬂammation in a patient with focal lung
inﬂammation where a biopsy was
contraindicated.
To the editor
Our patient, a 69-year old with a back-
ground of asthma, presented with a
14-month history of increasing wheeze
and cough, followed by acute deterioration
with breathlessness, weight loss and anor-
exia. On admission, he was haemodynamic-
ally unstable and severely hypoxaemic.
Thoracic computed tomography (CT)
revealed a right-sided pneumothorax with
peripheral ground glass opacities and con-
solidation throughout the left lung, raising
the possibility of chronic eosinophilic pneu-
monia. Tests revealed marked blood eosino-
philia of 2.3×109/L and an elevated
immunoglobulin E (IgE) at 910 kU/L; his
rheumatoid factor, antinuclear antibody
and antineutrophil cytoplasmic antibody
were negative. His IgG4 was elevated at
6.54 g/L (normal range (NR) 0–1.3 g/L),
suggestive of possible IgG4-related disease.
His pneumothorax was successfully aspi-
rated and he was given oxygen and empir-
ical broad-spectrum antibiotics. As he was
initially too unwell to undergo bronchos-
copy, a Tc-99m-eosinophil-single-photon
emission computed tomography (SPECT/
CT) scan was undertaken, as this novel
technique has been demonstrated previ-
ously to localise biopsy-proven pulmonary
eosinophilic inﬂammation.1
Tc-99m-labelled autologous eosinophils
were prepared using anti-CD16 microbe-
ads as described previously.2 Tc-99m-eosi-
nophils (192 MBq) were injected and
dynamic gamma camera imaging com-
menced, followed by SPECT; a single
low-dose CT to enable anatomical align-
ment was performed. Within 5 min,
uptake of labelled cells was visible on
planar images of his left lung (see
ﬁgure 1A) in addition to the expected
physiological uptake in the liver, spleen
and bone marrow. Increased activity was
further demonstrated in his left lung on
cross-sectional SPECT (see ﬁgure 1B).
Coronal, sagittal and transaxial SPECT/
CT images indicated focal uptake of radi-
olabelled eosinophils in regions of the
lung corresponding to abnormal areas on CT
(see ﬁgure 1C–E). These results provided evi-
dence of pulmonary eosinophilic inﬂamma-
tion and supported the early use of high-dose
oral corticosteroids, which led to rapid clin-
ical improvement. The patient’s serum on the
Figure 1 (A) Reframed composite image of the ﬁrst 5 min of the dynamic planar gamma
camera scan. Increased 99m-Tc-eosinophil uptake is visible in the left lung. LL, left lung; L, liver;
S, spleen. (B) Transaxial single-photon emission computed tomography (SPECT) image showing
increased activity in the vertebra and left lung (LL). L, left; R, right; V, vertebra. (C–E) Coronal,
sagittal and transaxial sections through the lung. SPECT/CT (lower panel) demonstrating focal
99m-Tc-eosinophil uptake in areas of abnormality in the CT (upper panel), (white arrows). (F)
Raw gamma counter results showing increased counts in the bronchoalveolar lavage ﬂuid (BALF)
compared with the BAL supernatant and natural background counts.
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day of the SPECT was analysed using a
multiplex cytokine and chemokine array
(MSD MULTI-SPOT Array System) and
showed raised levels (pg/mL) of interleukin
(IL)-5, 2.2 (NR <0.62 pg/mL), IL-15, 5.6
(NR <3.01 pg/mL); eotaxin, 428
(NR <145 pg/mL), eotaxin 3, 130 (NR
<8.73 pg/mL) and monocyte chemotactic
protein-4 (MCP-4), 358 (NR<117 pg/mL).
Within 48 h, his oxygenation had
improved, allowing bronchoscopy. The
bronchoalveolar lavage ﬂuid (BALF)
obtained had double the radioactive counts
per minute (cpm) (19.5 cpm/mL) than the
control ﬂuid (phosphate-buffered saline)
(9.3 cpm/mL) (see ﬁgure 1F). Counts in the
supernatant (9 cpm/mL) after centrifuga-
tion were identical to the control, demon-
strating that the radioactivity detected in
the BALF was cell associated.
The patient made a rapid and complete
recovery following treatment with oral
prednisolone.
This case demonstrates the ability of
Tc-99m-eosinophil-SPECT/CT to conﬁrm
pulmonary eosinophilic inﬂammation in
patients where acquisition of BALF or lung
biopsy was contraindicated. This method-
ology has the potential to be used clinically
alongside or as a non-invasive alternative
to conventional methods of detecting par-
enchymal eosinophilia. It may also aid in
the translation of novel therapeutics by
providing a platform to test their efﬁcacy
in reducing tissue eosinophilia.
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